-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumors send signals that impair normal blood flow, making them difficult to treat with various types of cancer treatments, including radiation, chemotherapy, targeted therapy and immunothera.
The scientists' assessment method involves measuring oxygen levels as an indicator of the degree of hypoxia and abnormal blood flow within the tum.
Jain and his colleagues used their microscopy system to examine the effects of two of their approaches to repairing abnormally reduced blood flow in tumor blood vessels: one using anti-angiogenic therapy, targeting pathways that affect blood vessel formation, and the other involving so-called An inhibitor of the angiotensin system, which reduces the pressure on tumor blood vessels created by tumor grow.
"Our microscopy analysis showed that although each approach relieved tumor hypoxia, the effects were mixed, for example, with varying outcomes depending on tumor type and dose," said co-author John.
"Understanding tumor hypoxia, anti-angiogenic therapy and losartan affect hypoxia -- how it affects disease progression and treatment resistance," said Ryan Chen, MD, PhD, a doctoral student at Steele who studied the study Assistant Professor of Laboratory Research, now at the University of Colorado School of Medici.
